Date:10/25/2011

4%4%1%9%   Total Customer Sales12%5%1%6%Business Unit Sales(in millions)First
Quarter 2010Second
Quarter 2010Third
Quarter 2010Fourth
Quarter 2010Total
2010   Research Essentials$
2$
7$
5$$
434   Research Specialties217207207214845   Research Biotech91838487345   Research Chemicals4203973964111,624   SAFC152157167171647   Total Customer Sales$
572$
554$
563$
582$
2,271First
Quarter 2011Second
Quarter 2011Third
Quarter 2011Fourth
Quarter 2011Total
2011   Research Essentials$
20$
24$
21$
-$
365   Research Specialties236236231-703   Research Biotech969494-284   Research Chemicals452454446-1,352   SAFC180183180-543   Total Customer Sales$
32$
37$
26$
-$
,895SIGMA-ALDRICH CORPORATIONSupplemental Financial Information - (Unaudited)Reconciliation of Reported Net Income to Adjusted Net IncomeNet IncomeDiluted Earnings (in millions)Per ShareThree Months EndedThree Months EndedSeptember 30,September 30,2011201020112010Reported net income$
7$
93$
.95$
.76Restructuring costs

130.010.02Impairment costs

-7-0.05Adjusted net income

$
8$
3$
.96$
.83Net IncomeDiluted Earnings (in millions)Per ShareNine Months EndedNine Months EndedSeptember 30,September 30,2011201020112010Reported net income$
349$
290$
2.84$
2.36Restructuring costs

590.040.07Impairment costs

-7-0.05Adjusted net income

$
354$
306$
2.88$
2.48Income Statement RatiosThree Months EndedNine Months EndedSeptember 30,September 30,2011201020112010Gross profit

53.2%52.9%52.8%53.0%S,G&A expenses

24.3%24.7%23.8%24.0%Operating income

25.6%23.4%25.7%24.9%Pretax income

25.2%23.3%25.4%24.6%Net income

18.7%16.5%18.4%17.2%Effective tax rate

25.9%29.0%27.4%30.3%Reconciliation of Reported Operating Income Margin to Adj
'/>"/>

SOURCE Sigma-Aldrich Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
3. Sigma-Aldrich(R) Receives Award From Michael J. Fox Foundation to Develop Parkinsons Disease Research Models
4. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
5. Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market
6. Sigma-Aldrich Announces SAGE(TM) Priority Partners Program; Seeks Researchers to Evaluate New Knockout Rat Models
7. Sigma-Aldrich Enters Distribution Agreement With Stemgent, Inc. to Offer Lentivirus-Based Gene Delivery Products for Regenerative Medicine and Stem Cell Research
8. Sigma-Aldrich Becomes the Sole U.S. and Canada Distributor of Kromasil(R) HPLC Columns Through Agreement With Eka Chemicals
9. Sigma-Aldrich to Present at the 28th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2010
10. Sigma-Aldrich(R) Licenses RAFT Polymerization Technology From CSIRO(R)
11. Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc.